J-Pharma Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024
Cash & Equivalents	4,452	2,302	1,073
Short-Term Investments	1.1	-	-
Cash & Short-Term Investments	4,453	2,302	1,073
Cash Growth	93.44%	114.49%	-
Other Receivables	46.89	16.18	23.87
Receivables	46.89	16.18	23.87
Prepaid Expenses	3.22	1.75	1.01
Other Current Assets	250.6	519.3	91.69
Total Current Assets	4,753	2,839	1,190
Long-Term Investments	-	14.96	14.96
Other Long-Term Assets	8.05	2.68	2.67
Total Assets	4,761	2,857	1,207
Accounts Payable	256.02	152.97	146.81
Accrued Expenses	29.19	27.47	45.33
Current Income Taxes Payable	35.41	0.99	0.99
Other Current Liabilities	57.51	270.51	6.58
Total Current Liabilities	378.12	451.93	199.7
Other Long-Term Liabilities	4.96	26.92	57.57
Total Liabilities	383.08	478.85	257.27
Common Stock	2,033	80	80
Additional Paid-In Capital	4,499	2,724	752.82
Retained Earnings	-2,466	-1,499	-1,652
Comprehensive Income & Other	312.9	1,072	1,770
Shareholders' Equity	4,378	2,378	950.12
Total Liabilities & Equity	4,761	2,857	1,207
Net Cash (Debt)	4,453	2,302	1,073
Net Cash Growth	93.44%	114.49%	-
Net Cash Per Share	352.18	282.62	171.19
Filing Date Shares Outstanding	17.98	14.59	6.27
Total Common Shares Outstanding	17.98	0.7	6.27
Working Capital	4,375	2,387	990.06
Book Value Per Share	243.47	3392.11	151.56
Tangible Book Value	4,378	2,378	950.12
Tangible Book Value Per Share	243.47	3392.11	151.56
Buildings	-	0.4	-
Machinery	-	2.92	-